Samsung Bioepis, G2GBio partner on long-acting obesity drug development

Samsung Bioepis and Epis NexLab, subsidiaries of Samsung Epis Holdings, have signed a joint research and licensing agreement with Korean biotech G2GBio to develop long-acting obesity treatments, the companies said Monday. The tripartite agreement aims to develop obesity drugs with extended dosing intervals and secure advanced drug delivery technologies using G2GBio’s microsphere-based platform. Under the deal, Samsung Bioepis will obtain development and commercialization rights to G2GBio’s pipel

By The Korea Herald